Article

[The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML].

Department of Hematology, Henan Cancer Hospital, Henan Institute of Hematology, Zhengzhou 450008, China.
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 03/2008; 29(2):110-2. pp.110-2
Source: PubMed

ABSTRACT To compare the efficacy of high-dose cytarabine (HD-Ara-C) based chemotherapy for post-remission treatment in patients with t(8;21) (q22;q22) AML-M2 and those with normal karyotype AML-M2.
AML-M2 patients were grouped into with (21 cases) or without (23 cases) t(8;21) (q22;q22) karyotype groups. After achieved remission by induction therapy, all patients received four cycles of HD-Ara-C (3 mg/m2 per 12 hours by three-hour infusion day 1 to day 3) with either mitoxantrone (7 mg m(-2) d(-1)) or aclarubicin (30 mg m(-2) d(-1)) or etoposide (70 mg m(-2) d(-1)) for 3d as post-remission treatment.
Relapse rate in the t(8;21) and the normal karyotype groups was 29% and 57% respectively (P<0.05); 3 year disease-free survival (DFS) rate was 71% and 43% respectively (P < 0.05). and 3 year over-all survival (OS) rate was 76% and 65% respectively (P >0.05).
Four cycles of high-dose cytarabine based combination chemotherapy as post-remission treatment improves long-term disease-free survival in patients with t(8;21) (q22;q22) AML-M2.

0 0
 · 
0 Bookmarks
 · 
17 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

3 year disease-free survival
 
3 year over-all survival
 
aclarubicin
 
chemotherapy
 
combination chemotherapy
 
day 3
 
efficacy
 
etoposide
 
HD-Ara-C
 
high-dose cytarabine
 
induction therapy
 
long-term disease-free survival
 
mitoxantrone
 
post-remission treatment
 
Relapse rate
 
remission
 
three-hour infusion day 1